Biosphere 2 Redux

A paneless window offers a view from an overhead walkway onto the artificial ocean of the Biosphere 2 Center, or B2C. It's a strange and fascinating sight, here under the Santa Catalina Mountains near dry little Oracle, Ariz., about 30 miles north of Tucson. Except for the walls and ceiling of glass triangles that enclose this million-gallon simulation of a Caribbean-type sea, the only obvious, unnatural object is a vacuum pump that provides a tidal pulse at the 25-foot deep end. Near the shallo

Written bySteve Bunk
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

The ocean biome is only one section of a 3.15-acre greenhouse, the world's biggest such controlled experimental site. There is also an equatorial rainforest, desert, savannah, marsh, and a three-chambered, managed forest. With an annual operating budget of about $17 million, much of it for energy costs, B2C is in the midst of a high-stakes struggle to remake itself as an environmental sciences research leader.

The facility's much-publicized original efforts of the 1990s--to provide a self-sustaining environment for human "biospherians," in part as an experimental precursor to colonizing space--have been replaced by a research focus on the effects of changing carbon dioxide (CO2) levels and temperature on ecosystems. The complex's original estimated construction price tag of $150 million, funded by Texas billionaire Ed Bass, has been supplemented by millions more in physical restructuring ever since Columbia University made B2C its western campus in 1996. Late last year, Columbia launched a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies